ADAM17 mediates hypoxia-induced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway

Molecular and Cellular Biochemistry

Volumn 380, Issue 1-2, 2013, Pages 57-66

  Wang, Xiang Jun ^a   Feng, Chang Wei ^a   Li, Min ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

A disintegrin and metalloproteinase 17 (ADAM17); Apoptosis; Chemoresistance; Cisplatin; Epidermal growth factor receptor (EGFR) phosphatidylinositol 3 kinase (PI3K) Akt signaling pathway; Hypoxia

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ADAM PROTEIN; ADAM17 PROTEIN; CASPASE 3; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LIPOCORTIN 5; METALLOPROTEINASE; PHOSPHATIDYLINOSITOL 3 KINASE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN KINASE B; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; DOWN REGULATION; HUMAN; HUMAN CELL; HYPOXIA; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STAINING; UPREGULATION; WESTERN BLOTTING;

ADAM PROTEINS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL HYPOXIA; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84879800528     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-013-1657-z     Document Type: Article

References (44)

1. Kizaka-Kondoh S, Inoue M, Harada H, Hiraoka M (2003) Tumor hypoxia: a target for selective cancer therapy. Cancer Sci 94:1021-1028
2. Wu XZ, Xie GR, Chen D (2007) Hypoxia and hepatocellular carcinoma: the therapeutic target for hepatocellular carcinoma. J Gastroenterol Hepatol 22:1178-1182
3. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP (2002) Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62:3387-3394
4. Liu L, Ning X, Sun L, Zhang H, Shi Y, Guo C, Han S, Liu J, Sun S, Han Z, Wu K, Fan D (2008) Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci 99:121-128
5. Arsham AM, Plas DR, Thompson CB, Simon MC (2004) Akt and hypoxia-inducible factor-1 independently enhance tumor growth and angiogenesis. Cancer Res 64:3500-3507
6. Mizukami Y, Li J, Zhang X, Zimmer MA, Iliopoulos O, Chung DC (2004) Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer. Cancer Res 64:1765-1772
7. Liu G, Roy J, Johnson EA (2006) Identification and function of hypoxia-response genes in Drosophila melanogaster. Physiol Genomics 25:134-141
8. Black RA (2002) Tumor necrosis factor-alpha converting enzyme. Int J Biochem Cell Biol 34:1-5
9. Yoshimura T, Tomita T, Dixon MF, Axon AT, Robinson PA, Crabtree JE (2002) ADAMs (a disintegrin and metalloproteinase) messenger RNA expression in Helicobacter pylori-infected, normal, and neoplastic gastric mucosa. J Infect Dis 185:332-340
10. Ding X, Yang LY, Huang GW, Wang W, Lu WQ (2004) ADAM17 mRNA expression and pathological features of hepatocellular carcinoma. World J Gastroenterol 10:2735-2739
11. Blanchot-Jossic F, Jarry A, Masson D, Bach-Ngohou K, Paineau J, Denis MG, Laboisse CL, Mosnier JF (2005) Up-regulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells. J Pathol 207:156-163
12. Zheng X, Jiang F, Katakowski M, Zhang ZG, Lu QE, Chopp M (2009) ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation. Cancer Biol Ther 8:1045-1054
13. Szalad A, Katakowski M, Zheng X, Jiang F, Chopp M (2009) Transcription factor Sp1 induces ADAM17 and contributes to tumor cell invasiveness under hypoxia. J Exp Clin Cancer Res 28:129
14. Rzymski T, Petry A, Kračun D, Rieß F, Pike L, Harris AL, Görlach A (2012) The unfolded protein response controls induction and activation of ADAM17/TACE by severe hypoxia and ER stress. Oncogene 31:3621-3634
15. Zheng X, Jiang F, Katakowski M, Kalkanis SN, Hong X, Zhang X, Zhang ZG, Yang H, Chopp M (2007) Inhibition of ADAM17 reduces hypoxia-induced brain tumor cell invasiveness. Cancer Sci 98:674-684
16. Liu L, Zhu XD, Wang WQ, Shen Y, Qin Y, Ren ZG, Sun HC, Tang ZY (2010) Activation of beta-catenin by hypoxia in hepatocellular carcinoma contributes to enhanced metastatic potential and poor prognosis. Clin Cancer Res 16:2740-2750
17. Etzerodt A, Maniecki MB, Møller K, Møller HJ, Moestrup SK (2010) Tumor necrosis factor α-converting enzyme (TACE/ADAM17) mediates ectodomain shedding of the scavenger receptor CD163. J Leukoc Biol 88:1201-1205
18. Lau CK, Yang ZF, Lam SP, Lam CT, Ngai P, Tam KH, Poon RT, Fan ST (2007) Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma. Cancer Biol Ther 6:1900-1907
19. Katakowski M, Jiang F, Zheng X, Gutierrez JA, Szalad A, Chopp M (2009) Tumorigenicity of cortical astrocyte cell line induced by the protease ADAM17. Cancer Sci 100:1597-1604
20. Katakowski M, Chen J, Zhang ZG, Santra M, Wang Y, Chopp M (2007) Stroke-induced subventricular zone proliferation is promoted by tumor necrosis factor-alpha-converting enzyme protease activity. J Cereb Blood Flow Metab 27:669-678
21. Lemjabbar H, Li D, Gallup M, Sidhu S, Drori E, Basbaum C (2003) Tobacco smoke-induced lung cell proliferation mediated by tumor necrosis factor alpha-converting enzyme and amphiregulin. J Biol Chem 278:26202-26207
22. Borrell-Pages M, Rojo F, Albanell J, Baselga J, Arribas J (2003) TACE is required for the activation of the EGFR by TGF-alpha in tumors. EMBO J 22:1114-1124
23. Kyula JN, Van Schaeybroeck S, Doherty J, Fenning CS, Longley DB, Johnston PG (2010) Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer. Clin Cancer Res 16:3378-3389
24. Kagawa K, Nakano A, Miki H, Oda A, Amou H, Takeuchi K, Nakamura S, Harada T, Fujii S, Yata K, Ozaki S, Matsumoto T, Abe M (2012) Inhibition of TACE activity enhances the susceptibility of myeloma cells to TRAIL. PLoS ONE 7:e31594
25. Liu WH, Chang LS (2010) Suppression of ADAM17-mediated Lyn/Akt pathways induces apoptosis of human leukemia U937 cells: Bungarus multicinctus protease inhibitor-like protein-1 uncovers the cytotoxic mechanism. J Biol Chem 285:30506-30515
26. Hilliard VC, Frey MR, Dempsey PJ, Peek RM Jr, Polk DB (2011) TNF-α converting enzyme-mediated ErbB4 transactivation by TNF promotes colonic epithelial cell survival. Am J Physiol Gastrointest Liver Physiol 301:G338-G346
27. Lizama C, Rojas-Benítez D, Antonelli M, Ludwig A, Bustamante-Marín X, Brouwer-Visser J, Moreno RD (2010) TACE/ADAM17 is involved in germ cell apoptosis during rat spermatogenesis. Reproduction 140:305-317
28. Arribas J, Esselens C (2009) ADAM17 as a therapeutic target in multiple diseases. Curr Pharm Des 15:2319-2335
29. Zheng X, Jiang F, Katakowski M, Lu Y, Chopp M (2012) ADAM17 promotes glioma cell malignant phenotype. Mol Carcinog 51:150-164
30. Zheng X, Jiang F, Katakowski M, Zhang X, Jiang H, Zhang ZG, Chopp M (2008) Sensitization of cerebral tissue in nude mice with photodynamic therapy induces ADAM17/TACE and promotes glioma cell invasion. Cancer Lett 265:177-187
31. Lin P, Sun X, Feng T, Zou H, Jiang Y, Liu Z, Zhao D, Yu X (2012) ADAM17 regulates prostate cancer cell proliferation through mediating cell cycle progression by EGFR/PI3K/AKT pathway. Mol Cell Biochem 359:235-243
32. Thabet MM, Huizinga TW (2006) Drug evaluation: apratastat, a novel TACE/MMP inhibitor for rheumatoid arthritis. Curr Opin Investig Drugs 7:1014-1019
33. Sparano JA, Bernardo P, Stephenson P, Gradishar WJ, Ingle JN, Zucker S, Davidson NE (2004) Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol 22:4683-4690
34. Tape CJ, Willems SH, Dombernowsky SL, Stanley PL, Fogarasi M, Ouwehand W, McCafferty J, Murphy G (2011) Cross-domain inhibition of TACE ectodomain. Proc Natl Acad Sci USA 108:5578-5583
35. Richards FM, Tape CJ, Jodrell DI, Murphy G (2012) Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo. PLoS ONE 7:e40597
36. Gillies RJ, Raghunand N, Karczmar GS, Bhujwalla ZM (2002) MRI of the tumor microenvironment. J Magn Reson Imaging 16:430-450
37. Jiang J, Tang YL, Liang XH (2011) EMT: a new vision of hypoxia promoting cancer progression. Cancer Biol Ther 11:714-723
38. Ke Q, Costa M (2006) Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 70:1469-1480
39. Charbonneau M, Harper K, Grondin F, Pelmus M, McDonald PP, Dubois CM (2007) Hypoxia-inducible factor mediates hypoxic and tumor necrosis factor alpha-induced increases in tumor necrosis factor-alpha converting enzyme/ADAM17 expression by synovial cells. J Biol Chem 282:33714-33724
40. Laemmle A, Lechleiter A, Roh V, Schwarz C, Portmann S, Furer C, Keogh A, Tschan MP, Candinas D, Vorburger SA, Stroka D (2012) Inhibition of SIRT1 impairs the accumulation and transcriptional activity of HIF-1α protein under hypoxic conditions. PLoS ONE 7:e33433
41. Saponaro C, Malfettone A, Ranieri G, Danza K, Simone G, Paradiso A, Mangia A (2013) VEGF, HIF-1α expression and MVD as an angiogenic network in familial breast cancer. PLoS ONE 8:e53070
42. Zhdanov AV, Dmitriev RI, Papkovsky DB (2012) Bafilomycin A1 activates HIF-dependent signalling in human colon cancer cells via mitochondrial uncoupling. Biosci Rep 32:587-595
43. Kanda K, Komekado H, Sawabu T, Ishizu S, Nakanishi Y, Nakatsuji M, Akitake-Kawano R, Ohno M, Hiraoka Y, Kawada M, Kawada K, Sakai Y, Matsumoto K, Kunichika M, Kimura T, Seno H, Nishi E, Chiba T (2012) Nardilysin and ADAM proteases promote gastric cancer cell growth by activating intrinsic cytokine signalling via enhanced ectodomain shedding of TNF-α. EMBO Mol Med 4:396-411
44. Wang YY, Lo GH, Lai KH, Cheng JS, Lin CK, Hsu PI (2003) Increased serum concentrations of tumor necrosis factor-alpha are associated with disease progression and malnutrition in hepatocellular carcinoma. J Chin Med Assoc 66:593-598